People · Operator
Named in public records as an officer, director or promoter · active 2016–2024 · Biotechnology, Other Health Care
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Avalo Therapeutics, Inc. | — | Biotechnology | Series D+ | $181.8M | $1.6B | 2016 |
| Trailhead Biosystems Inc. | — | Biotechnology | Series B | $41.7M | $75.7M | 2020 |
| Goldcup 12446 AB | — | Other Health Care | Series B | $29.7M | $657.1M | 2016 |
Magnus Persson at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Magnus Persson on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Isaac Blech | 1 | 14 |
| David Parker | 1 | 11 |
| MICHAEL KAUFMAN | 1 | 7 |
| EUGENE A. BAUER | 1 | 7 |
| Aaron Kantoff | 1 | 6 |
| Sol J. Barer | 1 | 6 |
| Craig Nemiroff | 1 | 4 |
| Houman Hemmati | 1 | 4 |
| Phil Gutry | 1 | 4 |
| Christopher Sullivan | 1 | 3 |
| ULI HACKSELL | 1 | 3 |
| Behshad Sheldon | 1 | 3 |
| Herbert Hooper | 1 | 3 |
| Frank A. Torti | 1 | 3 |
| Eugene Bauer | 1 | 3 |
| Isaac A. Blech | 1 | 3 |
| Hans Andreasson | 1 | 2 |
| John Kaiser | 1 | 2 |
| Isaac M. Blech | 1 | 2 |
| Thomas Aasen | 1 | 2 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.